# US 10,118,954 B2 · Apelin analogues > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,118,954 B2 - Document ID: US10118954B2 - Status: Granted - Kind: B2 - Application number: 15/307,248 - Filed: 2015-04-29 - Published: 2017-03-09 - Granted: 2018-11-06 - Earliest claimed: 2014-04-29 - Assignees: Univeristy of Ulster - Applicants: University of Ulster - Inventors: Finbarr Paul Mary O'Harte; Peter Raymond Flatt - Web page: https://patentgrep.com/patent/US10118954B2 ## CPC - C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695) - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 5/48: of the pancreatic hormones - C07K 14/52: Cytokines; Lymphokines; Interferons - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A pharmaceutical composition with a peptide analog of apelin, and a method of treatment for various conditions are described. An exemplary embodiment is a peptide analog comprising at least residues 2-13 of SEQ ID NO: 1 and further comprising at least a substitution or modification at residue 13 of SEQ ID NO: 1. A pharmaceutical composition comprising the peptide analog of the present invention and method of treatment for diabetes, stimulating insulin release, and moderating blood glucose excursions by administering the peptide analog of the present invention to a patient in need thereof are described. ## Claims ### Claim 1 A peptide analogue comprising at least residues 2-13 of SEQ ID NO: 1 and further comprising at least one from the group consisting of a substitution and a modification at residue 13 or SEQ ID NO: 1; those amino acids present at positions 2-7 and 9-12 of the peptide analogue are unsubstituted with respect to the corresponding residues of SEQ ID NO: 1; an N-terminal addition with at least one from the group consisting of pGlu (5-oxoproline), an acetyl moiety, an acyl moiety, and an acylated moiety; and a modification at residue 8 of SEQ ID NO: 1. ### Claim 2 (depends on 1) The peptide analogue of claim 1, wherein the peptide analogue is at least one from the group consisting of pGlu (Tyr13)apelin-13, (pGlu)apelin-13-amide, and, pGlu(Lys8GluPAL)apelin-13-amide. ### Claim 3 (depends on 1) A pharmaceutical composition comprising the peptide analogue of claim 1 in association with a pharmaceutically acceptable excipient. ### Claim 4 (depends on 1) The peptide analogue of claim 1, wherein residue 13 is the C-terminal residue and the modification at residue 13 is the substitution of the terminal carboxyl group by an amide group. ### Claim 5 A peptide analogue consisting of at least residues 2-13 of SEQ ID NO: 1, wherein residue 13 is the C-terminal residue and the terminal carboxyl group of residue 13 is replaced by an amide group; and comprising an N-terminal addition of pGlu (5-oxoproline) or an acetyl, acyl or acylated moiety; and comprising a modification at residue 8 of SEQ ID NO: 1. ### Claim 6 (depends on 5) The peptide of claim 5, wherein the modification at residue 8 is the fatty acid addition at an epsilon amino group of residue 8. ### Claim 7 A peptide comprising pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys(gluPAL)-Gly-Pro-Met-Pro-Phe-amide. ### Claim 8 (depends on 7) A pharmaceutical composition comprising the peptide analogue of claim 7 in association with a pharmaceutically acceptable excipient. ### Claim 9 (depends on 1) A method of treating diabetes, the method comprising administering to an individual (pGlu)apelin 13 amide or the peptide analogue of claim 1. ### Claim 10 (depends on 1) A method of stimulating insulin release, the method comprising administering to an individual (pGlu)apelin-13 amide or the peptide analogue of claim 1. ### Claim 11 (depends on 1) A method of moderating blood glucose excursions, the method comprising administering to an individual (pGlu)apelin-13 amide or the peptide analogue of claim 1. ### Claim 12 (depends on 1) A method of increasing food intake or increasing body weight, the method comprising administering to an individual (pGlu)apelin-13 amide or the peptide analogue of claim 1. ### Claim 13 (depends on 1) A method of suppressing appetite or reducing body weight, the method comprising administering to an individual (pGlu)apelin-13 amide or the peptide analogue of claim 1. ### Claim 14 (depends on 1) A method of reducing blood pressure, the method comprising administering to an individual (pGlu)apelin-13 amide or the peptide analogue of claim 1.